BioDelivery Sciences International announced Monday that it has secured an additional $20.7 in debt funding to support the commercial launch of its drug Bunavail.
BioDelivery Sciences secured the loan from MidCap Financial, bringing its total debt with MidCap to $30 million.
Prescriptions for Bunavail, which is a treatment for opioid dependence, totaled nearly 11,000 in the first quarter. The drug was approved by the Food and Drug Administration last year.
BioDelivery Sciences is seeking to broaden market access to Bunavail. Eight state Medicaid plans are now covering the treatment representing more than 30,000 prescriptions per month.